Navigation Links
Added benefit of linagliptin is not proven
Date:8/3/2012

Linagliptin (trade name: Trajenta) has been approved since August 2011 to improve blood glucose control ("glycaemic control") in adults with type 2 diabetes mellitus whose elevated blood glucose levels are inadequately controlled by diet and exercise. It is an option for patients who do not tolerate or should not take the usual treatment with the drug metformin. Moreover, linagliptin can be added if treatment with metformin alone is not sufficient.

In an early benefit assessment pursuant to the "Act on the Reform of the Market for Medicinal Products" (AMNOG), the German Institute for Quality and Efficiency in Health Care (IQWiG) examined whether linagliptin offers an added benefit versus the appropriate comparator therapy specified by the Federal Joint Committee (G-BA). No such added benefit can be inferred from the dossier, as the drug manufacturer deviated from the G-BA's specifications and chose a different comparator therapy.

Approval status distinguishes between three treatment situations

The appropriate comparator therapy specified by the G-BA distinguishes between three treatment situations:

  • Administration of linagliptin alone (monotherapy) as a substitute for metformin if this drug is not tolerated by patients or should not be taken because of impaired kidney function. To assess the added benefit, linagliptin monotherapy should be compared with a drug from the sulfonylurea class (glibenclamide or glimepiride).

  • Dual therapy combines linagliptin and metformin and is indicated if treatment with metformin alone is insufficient to control blood glucose levels. To assess the added benefit, dual therapy with linagliptin should be compared with a combination of metformin and a sulfonylurea (glibenclamide or glimepiride).

  • Triple therapy combines linagliptin, metformin and a sulfonylurea and is used if dual therapy with metformin and a sulfonylurea is no longer a sufficient treatment option. To assess the added benefit, triple therapy should be compared with a combination of insulin and metformin.

Drug manufacturer chose a gliptin as comparator therapy

In its dossier, the manufacturer compared linagliptin with a different drug from the gliptin class (sitagliptin) in all three treatment situations and thereby deviated from the specifications of the G-BA. However, in IQWiG's opinion, the manufacturer insufficiently justified this deviation. For the dossier assessment IQWiG therefore uses the appropriate comparator therapy specified by the G-BA.

In the dossier, the manufacturer makes no statements on the extent and probability of an added benefit of linagliptin versus the appropriate comparator therapy specified by the G-BA. Studies that would have been relevant for this purpose were explicitly excluded from the assessment. The manufacturer's dossier therefore provides no proof of an added benefit of linagliptin versus the G-BA's appropriate comparator therapy. This applies to all three treatment situations mentioned above, that is, monotherapy, dual and triple combination therapy.

In the dossier the manufacturer did not determine an added benefit of linagliptin versus the comparator therapy they had chosen themselves (sitagliptin).

G-BA decides on the extent of added benefit

The procedure for inferring the overall conclusion on the extent of added benefit is a proposal from IQWiG. The G-BA, which has opened a formal commenting procedure, will decide on the extent of added benefit.


'/>"/>
Contact: Dr. Anna-Sabine Ernst
presse@iqwig.de
49-022-135-6850
Institute for Quality and Efficiency in Health Care
Source:Eurekalert

Related medicine news :

1. Collagenase for Dupuytrens contracture: Added benefit not proven
2. Abiraterone: Indication of considerable added benefit in certain patients
3. Nurse Alert Provides Added Level of Senior Alert Care With New Nurse Triage Feature
4. Tafamidis: Approval denotes proven added benefit
5. No Added Cancer Risk From Hip Replacement Materials: Study
6. Modest Weight Loss Can Reap Prolonged Health Benefits
7. Landmark HIV treatment-as-prevention study shows additional health benefits, cost-effectiveness
8. Benefits of HIV drugs rise -- but less than previously believed, Penn study shows
9. The Health Benefits, and Risks, of Alcohol
10. Despite clear benefits, heart failure clinics are rarely utilized
11. Expert Panel Suggests PSA Test May Benefit Some Men
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2016)... ... December 07, 2016 , ... ODU, ... to the US market its advanced highly customizable contact technology solutions. , ODU ... These advanced technologies are ideal for a wide range of applications that require ...
(Date:12/7/2016)... CA (PRWEB) , ... December 07, 2016 , ... ... provides insurance and financial consultation services to residents in the Sacramento/Folsom region, is ... Another Chance treatment facility. , The Another Choice Another Chance treatment center in ...
(Date:12/7/2016)... ... ... One of two inventors from Glen Burnie, Md., has a granddaughter who ... is why the co-inventor and I have designed a new and better way to ... of the patent-pending AV-AIR, a device that serves as an alternative to conventional methods ...
(Date:12/7/2016)... , ... December 07, 2016 , ... A. Kevin Spann ... and families throughout the Five Boroughs, is launching a charity drive to raise funds ... continue the traditions and spirit of marines and Navy FMF Corpsmen. Working closely with ...
(Date:12/7/2016)... , ... December 07, 2016 , ... Sharon Kleyne, host ... Climate Change and Your Health on Voice of America, declared on her radio program ... attention to the fact that when these bullies attack leaders in corporate America, they ...
Breaking Medicine News(10 mins):
(Date:12/7/2016)... Diplomat Pharmacy, Inc. (NYSE: DPLO) has launched Diplomat Specialty ... IV Infusion Professional, BioRx, MedPro Rx, and XAS Infusion Suites. ... diplomat.is/specialty-infusion .  ... Diplomat Specialty Pharmacy (PRNewsFoto/Diplomat Pharmacy, Inc.) ... "As we continue to build on the work we have ...
(Date:12/7/2016)... , Dec. 7, 2016  Varian Medical Systems (NYSE: ... its previously announced plans to separate its Imaging Components ... a tax-free distribution to Varian stockholders of common stock ... that will hold the Imaging Components business.  As part ... executed by the end of January 2017, Varian will ...
(Date:12/7/2016)... , Dec. 7, 2016  Ionis Pharmaceuticals, Inc. (NASDAQ: ... will present a company overview at the BMO Capital Markets Prescriptions ... New York, NY . A live webcast of ... of the Ionis website.  The replay will be available within 48 ... ...
Breaking Medicine Technology: